Biological behaviour and response to treatment of neuroendocrine ovarian metastases

#3778

Introduction: Neuroendocrine ovarian metastases (NOM) predominantly derive from midgut neuroendocrine tumors (NETs) and develop in about 25% of female patients. Little is known of the treatment response of NOM.

Aim(s): To evaluate the efficacy of different management options for patients with NOM, including somatostatin analogues (SSAs), peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and oophorectomy.

Materials and methods: Records were screened for all patients with well-differentiated NOM of midgut origin that presented in our center between 1991 and 2022. Tumor response was determined using RECIST 1.1. Progression free survival (PFS) and tumor growth rate (TGR) were compared between ovarian and extra-ovarian metastases. The effect of oophorectomy on overall survival (OS) was determined after propensity score matching.

Conference:

Presenting Author:

Authors: Mulders M, de Lussanet de La Sablonière Q, van Velthuysen M, Hofland J, de Herder W,

Keywords: neuroendocrine, ovary, PRRT, SSA, oophorectomy, tumor, growth, rate, PFS, OS,